These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 33652352

  • 1. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY.
    Eur J Med Chem; 2021 Apr 15; 216():113265. PubMed ID: 33652352
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z, Yu P, Dong L, Wang W, Duan S, Wang B, Gong X, Ye L, Wang H, Tian J.
    J Med Chem; 2021 Jul 22; 64(14):10286-10296. PubMed ID: 34253025
    [Abstract] [Full Text] [Related]

  • 5. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L, Chen Y, Zhang C, Jiao B, Liang S, Tan Q, Chai H, Yu W, Qian Y, Yang H, Yao W, Yu J, Luo Y, Plewe M, Wang J, Han XR, Liu J.
    J Med Chem; 2020 Dec 10; 63(23):14562-14575. PubMed ID: 33058680
    [Abstract] [Full Text] [Related]

  • 6. Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights.
    Mahajan AT, Shivani, Datusalia AK, Coluccini C, Coghi P, Chaudhary S.
    Molecules; 2024 Jul 29; 29(15):. PubMed ID: 39124968
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ, Jaworski C, Tung D, Wängler C, Wängler B, Schirrmacher R.
    Expert Opin Ther Pat; 2020 May 29; 30(5):325-339. PubMed ID: 32129124
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS, Sigal D.
    Curr Oncol Rep; 2019 Feb 04; 21(2):14. PubMed ID: 30715603
    [Abstract] [Full Text] [Related]

  • 17. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V.
    Expert Opin Ther Pat; 2017 Jun 04; 27(6):733-751. PubMed ID: 28270010
    [Abstract] [Full Text] [Related]

  • 18. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B, Zhang W, Liu X, Zou F, Wang J, Liu Q, Wang A, Hu Z, Chen Y, Qi S, Jiang Z, Chen C, Hu C, Wang L, Wang W, Liu Q, Liu J.
    Eur J Med Chem; 2020 Dec 01; 207():112744. PubMed ID: 32949955
    [Abstract] [Full Text] [Related]

  • 19. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
    Zhang Y, Liu Y, Zhou Y, Zhang Q, Han T, Tang C, Fan W.
    Bioorg Med Chem Lett; 2021 Jan 01; 31():127712. PubMed ID: 33246108
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.